{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:44:42Z","timestamp":1793994282573,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xcrm.2026.102989","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:18:56Z","timestamp":1786634336000},"page":"102989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Individualized antisense oligonucleotide treatment eligibility of patients living with neurodevelopmental diseases"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-654X","authenticated-orcid":false,"given":"Annemieke","family":"Aartsma-Rus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Melo","family":"de Gusmao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke","family":"van Roon-Mom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holm","family":"Graessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn Wein","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Wei-Wen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Schuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102989_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.744532","volume":"12","author":"Aartsma-Rus","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.102989_bib2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/22143602251385045","article-title":"Real-world evidence on nusinersen treatment of persons with SMA: a focused review","volume":"13","author":"Matesanz","year":"2026","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2026.102989_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/nat.2024.0091","article-title":"Addressing the Needs of Nano-Rare Patients","volume":"35","author":"Crooke","year":"2025","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.xcrm.2026.102989_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf346","article-title":"The N=1 Collaborative: advancing customized nucleic acid therapies through collaboration and data sharing","volume":"53","author":"Belgrad","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102989_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102615","article-title":"Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation","volume":"36","author":"Sch\u00fcle","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2026.102989_bib6","article-title":"Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics","volume":"5","author":"Aartsma-Rus","year":"2024","journal-title":"Ther. Adv. Rare Dis."},{"key":"10.1016\/j.xcrm.2026.102989_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2021.0039","article-title":"Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives","volume":"32","author":"Synofzik","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.xcrm.2026.102989_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkag504","article-title":"Addressing the needs of nano-rare patients: the n-Lorem experience","volume":"54","author":"Crooke","year":"2026","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2026.102989_bib9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib10","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib11","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/s41591-024-03078-4","article-title":"AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient","volume":"30","author":"Dowling","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41573-024-01059-3","article-title":"The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap","volume":"24","author":"Jonker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2026.102989_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ajhg.2025.02.017","article-title":"Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments","volume":"112","author":"Cheerie","year":"2025","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.xcrm.2026.102989_bib14","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1172\/JCI80554","article-title":"Ube3a reinstatement identifies distinct developmental windows in a murine Angelman syndrome model","volume":"125","author":"Silva-Santos","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102989_bib15","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1038\/s41591-025-03784-7","article-title":"The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial","volume":"31","author":"Hipp","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa2506295","article-title":"Zorevunersen in Children and Adolescents with Dravet Syndrome","volume":"394","author":"Laux","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib18","article-title":"AAV9\/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1-\/- mice","volume":"135","author":"Guo","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102989_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature16159","article-title":"Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides","volume":"528","author":"Sztainberg","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102989_bib20","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/hmg\/ddae135","article-title":"Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels","volume":"33","author":"Bajikar","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2026.102989_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.25676","article-title":"Scn8a Antisense Oligonucleotide Is Protective in Mouse Models of SCN8A Encephalopathy and Dravet Syndrome","volume":"87","author":"Lenk","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2026.102989_bib22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/ana.26861","article-title":"Long-Term Downregulation of the Sodium Channel Gene Scn8a Is Therapeutic in Mouse Models of SCN8A Epilepsy","volume":"95","author":"Hill","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.xcrm.2026.102989_bib23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/s41591-026-04314-9","article-title":"Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy","volume":"32","author":"Nakayama","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib24","series-title":"Facilitator's Guide to Participatory Decision-Making","author":"Kaner","year":"2014"},{"key":"10.1016\/j.xcrm.2026.102989_bib25","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41591-025-03656-0","article-title":"Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy","volume":"31","author":"Wagner","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib26","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib27","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(25)00513-6","article-title":"Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series","volume":"405","author":"Shneider","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102989_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.xcrm.2026.102989_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/hmg\/ddt421","article-title":"Rescue of behavioral and EEG deficits in male and female Mecp2-deficient mice by delayed Mecp2 gene reactivation","volume":"23","author":"Lang","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.xcrm.2026.102989_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq4529","article-title":"Modulating alternative splicing of MECP2 is a potential therapeutic strategy for Rett syndrome","volume":"18","author":"Tirumala","year":"2026","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102989_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/humu.10028","article-title":"Clinical and molecular basis of classical lissencephaly: Mutations in the LIS1 gene (PAFAH1B1)","volume":"19","author":"Cardoso","year":"2002","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.xcrm.2026.102989_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/hmg\/6.2.157","article-title":"Point mutations and an intragenic deletion in LIS1, the lissencephaly causative gene in isolated lissencephaly sequence and Miller-Dieker syndrome","volume":"6","author":"Lo Nigro","year":"1997","journal-title":"Hum. Mol. Genet."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:45:35Z","timestamp":1789591535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666379126004064"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102989","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized antisense oligonucleotide treatment eligibility of patients living with neurodevelopmental diseases","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102989"}}